Nasdaq Nordic: Nasdaq Helsinki welcomes Optomed

December 5, 2019 - Nasdaq (Nasdaq: NDAQ) announced that trading in Optomed Plc
shares (short name: OPTOMED) commence today on the prelist of Nasdaq Helsinki.
Optomed is a small cap company within the Health Care sector. The company's
shares are estimated to move to the main market of Nasdaq Helsinki on December
9, 2019. Optomed is the 55th company to be admitted to trading on Nasdaq's
Nordic markets* in 2019, and it represents the seventh listing on Nasdaq
Helsinki in 2019. 

Optomed is a Finnish medical technology company and one of the leading
providers of handheld fundus cameras. Optomed combines handheld screening
devices with software and artificial intelligence with the aim to transform the
diagnostic process of blinding eye-diseases such as rapidly increasing diabetic
retinopathy. In its business Optomed focuses on eye-screening devices and
software solutions related R&D in Finland and sales through different channels
in over 60 countries. The company has an extensive portfolio of 52
international patents protecting the technology. In 2018, Optomed's revenue
reached EUR 12.7 million and pro forma net sales with the acquisition of
Commit; Oy amounted to EUR 14.5 million. At the end of September 2019, Optomed
employed 105 professionals. For more information, please visit www.optomed.com 

"We are extremely happy and proud of the wide interest expressed in our initial
public offering. Optomed is a Finnish medical technology company in expansion
phase and one of the leading providers of handheld fundus cameras. The purpose
of our offering was to raise funds to implement our growth strategy, to
strengthen the company's recognition and to increase the liquidity of our
shares. With the offering, Optomed received over 2,300 new owners, and our
shares were subscribed by Finnish and international institutional investors and
private investors in Finland and Sweden. The successful offering serves as a
solid base to continue our work on the global challenge of diabetic
retinopathy. We are passionate about developing unique technological
innovations, which enable eye screenings for anyone in need globally. We want
to warmly thank everyone involved in our offering for their trust and
willingness to take part in our growth story",comments CEO Seppo Kopsala of
Optomed. 

"We congratulate Optomed on the successful completion of its IPO, and warmly
welcome the company to Nasdaq Helsinki", said Henrik Husman, President of
Nasdaq Helsinki. "It is truly exciting to have an innovative healthcare
technology company to join our markets, and we look forward to supporting
Optomed with the strong liquidity and international investor reach that a
listing on our main market brings." 

*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki,
Nasdaq Iceland and Nasdaq Stockholm 

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital
markets and other industries. Our diverse offering of data, analytics, software
and services enables clients to optimize and execute their business vision with
confidence. To learn more about the company, technology solutions and career
opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com. 

Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland, Nasdaq Riga, Nasdaq
Stockholm, Nasdaq Tallinn, Nasdaq Vilnius, Nasdaq Clearing and Nasdaq Broker
Services are respectively brand names for the regulated markets of Nasdaq
Copenhagen A/S, Nasdaq Helsinki Ltd., Nasdaq Iceland hf., Nasdaq Riga, AS,
Nasdaq Stockholm AB, Nasdaq Tallinn AS, AB Nasdaq Vilnius, Nasdaq Clearing AB
and Nasdaq Broker Services AB. Nasdaq Nordic represents the common offering by
Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm. Nasdaq
Baltic represents the common offering by Nasdaq Tallinn, Nasdaq Riga and Nasdaq
Vilnius 

Cautionary Note Regarding Forward-Looking Statements

The matters described herein contain forward-looking statements that are made
under the Safe Harbor provisions of the Private Securities Litigation Reform
Act of 1995. These statements include, but are not limited to, statements about
Nasdaq and its products and offerings. We caution that these statements are not
guarantees of future performance. Actual results may differ materially from
those expressed or implied in the forward-looking statements. Forward-looking
statements involve a number of risks, uncertainties or other factors beyond
Nasdaq's control. These factors include, but are not limited to factors
detailed in Nasdaq's annual report on Form 10-K, and periodic reports filed
with the U.S. Securities and Exchange Commission. We undertake no obligation to
release any revisions to any forward-looking statements. 

FOR MEDIA RELATIONS:
Maarit Bystedt
tel. [phone]
[e-mail]